Vaxcell Bio Therapeutics

What Vaxcell Bio Therapeutics does

Vaxcell Bio Therapeutics (박셀바이오) is a publicly traded (KRX: 323990) Korean biotechnology company founded in 2010 and headquartered in Hwasun, South Korea, with a Seoul office. The company develops anti-cancer immunotherapy platforms spanning NK cell therapy, CAR-T cell therapy, targeted anticancer agents, and antibody platforms, targeting both human oncology indications (liver cancer, small cell lung cancer, pancreatic cancer, solid and hematologic tumors, autoimmune disease) and veterinary indications.

Its lead commercial product, VCB-2401 (Vaxleukin-15 / 박스루킨-15주), is a recombinant canine interleukin-15 expressed in E. coli that activates NK and T cells to enhance anti-tumor immunity; it received Korea's first pet-specific immune anticancer drug approval from the Animal and Plant Quarantine Agency in August 2024 (canine mammary tumor post-surgery immune adjuvant) and indication expansion to include lymphoma in September 2025. The companion consumer brand Goldmmune (골드뮨) sells liquid, bite, and puree pet supplements covering immune, joint, skin/coat, and eye health, distributed through Korean veterinary hospitals and a DTC e-commerce site (goldmmune.com).

Commercial revenue is generated via B2B prescription sales of VCB-2401 through Korean veterinary hospitals and B2B/B2C sales of Goldmmune supplements via veterinary and DTC channels; pricing is not publicly disclosed. Recent strategic activity includes Japanese patent registration of an Anti-PD-L1 CAR-T therapy (January 2026), CPHI China 2026 participation, a Taiwan pet healthcare partnership with Lever Genetics (March 2026), an AI cell and gene therapy MOU with IT-Izes (July 2026), participation in Korea's national new drug development project for a MYO1D-targeted anticancer agent (November 2025), and an AMD drug delivery research MOU with Seoul National University College of Pharmacy (November 2025). The company operates from an integrated bio hub in Hwasun opened December 2025 and has 11–50 employees.

Name

Vaxcell Bio Therapeutics

Legal name

박셀바이오

Website

https://vaxcell-bio.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Vaxcell Bio Therapeutics (박셀바이오) is a Korean biotech developing anti-cancer immunotherapies, including Korea's first pet-specific immune anticancer drug VCB-2401 (Vaxleukin-15) and Goldmmune pet supplements, alongside a human oncology pipeline in NK cell, CAR-T, and antibody platforms.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Companion Animal Therapeutics (Rx) (HLAMAEAA)

akta.pro secondary industries

Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK), Specialty & Condition-Specific Nutraceuticals (e.g., Liver, Eye, Endocrine) (HLAMALAO)

Keywords

• Pet oncology pharmaceuticals
• Animal immunotherapy drugs
• Veterinary biopharmaceuticals
• Companion animal healthcare
• Pet health supplements

Headquarters

HQ city

Hwasun

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pet Immune Anticancer Drugs: Sales of VCB-2401 (Vaxleukin-15), Korea's first pet-specific immune anticancer drug for dogs, approved for mammary tumors and lymphoma
2. Pet Health Supplements: Goldmmune product line including liquid supplements, bites, and health functional foods for pets sold through veterinary hospitals and direct channels

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Vaxcell Bio Therapeutics develops and commercializes veterinary biopharmaceuticals and pet health supplements. Its flagship product VCB-2401 (Vaxleukin-15) is a recombinant canine interleukin-15 based immunotherapy drug, approved in South Korea as the first pet-specific immune anticancer drug for canine mammary tumors and lymphoma. The company also sells the GOLDMMUNE line of pet health functional supplements (liquid formulas, bite supplements, puree) for dogs and cats, and maintains an R&D pipeline covering human NK cell therapy, CAR-T therapy, targeted anticancer drugs, and antibody platforms.

Product overview

Vaxcell Bio Therapeutics is a biopharmaceutical company developing anti-cancer immunotherapies. The company operates two main product lines: VCB-2401 (Vaxleukin-15), an animal immune anti-cancer drug and the company's first approved product, and GOLDMMUNE, a pet health functional supplement brand. The product portfolio includes liquid formulas (with mountain goat protein and Fukoidan), bite supplements (bone & joint, skin & coat, eye & tear formulations), and puree supplements for cats, all designed to enhance immune function in companion animals.

Differentiator

Problem solved

Functional benefit

Brands

• Vaxleukin-15: Recombinant canine IL-15 based immune adjuvant anti-cancer drug for dogs, approved for mammary tumors and lymphoma. Marketed as 박스루킨-15주 (Vaxleukin-15 inj.)
• Goldmmune
• 박스루킨-15

Products and services

• VCB-2401 (Vaxleukin-15 / 박스루킨-15) A recombinant canine interleukin-15 (IL-15) based immunotherapy drug developed using an E. coli expression system, administered as an injectable for dogs. It activates NK cells and T cells to enhance anticancer immunity and is approved as an immune adjuvant therapy for canine mammary tumors and lymphoma.
• GOLDMMUNE (골드뮨) A pet health functional supplement line designed to enhance pets' anti-cancer immunity, improve digestive function, and prevent internal diseases. The line includes liquid formulas (with mountain goat protein and fucoidan), bite supplements (bone & joint, skin & coat, eye & tear), and puree supplements for cats. Sold through veterinary hospitals and via direct-to-consumer e-commerce at goldmmune.com.

Quantifiable outcome

• 40-50% cancer incidence in dogs over 8 years old
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• IT-Izes (아이티아이즈)coreStrategic or Co-development Partner · 1 July 2026MOU signed for AI-based next-generation cell and gene therapy development. Combines Vaxcell Bio's immunotherapy expertise with IT-Izes' AI capabilities to accelerate development of advanced cell and gene therapies.
• Lever Genetics (레버 지네틱스)coreStrategic or Co-development Partner · 11 March 2026Pet healthcare partnership with Taiwan-based Lever Genetics. Aims to expand pet health product distribution and development in Taiwan and international markets.
• National New Drug Development Project (국가신약개발사업)coreStrategic or Co-development Partner · 24 November 2025Government-supported national project for MYO1D-targeted anticancer drug development. Vaxcell Bio participates as a technology provider in this national initiative.
• Seoul National University College of Pharmacy (서울대 종합약학연구소)coreStrategic or Co-development Partner · 13 November 2025MOU for joint research on age-related macular degeneration (AMD) drug delivery system (DDS) treatments. Combines academic research capabilities with company's drug development expertise.

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Zoetis: Largest global animal health company with extensive companion animal oncology and immunology products; serves as the broad incumbent that Vaxcell would compete against in any cross-border pet oncology expansion.
• Elanco Animal Health: Global animal health leader formed partly via Aratana acquisition, with companion animal therapeutics portfolio including oncology; relevant incumbent comparable for Vaxcell's commercial-stage pet franchise.

Emerging players

• Anivive Lifesciences: US-based emerging pet therapeutics company developing novel oncology and immunology products for companion animals; directly comparable as a smaller, focused pet oncology peer.
• Aratana Therapeutics: Pioneering pet therapeutics company (now part of Elanco) that built the early pet oncology therapeutics category; a relevant comparable for Vaxcell's commercial-stage pet cancer drug positioning.

Direct peers

• Vetoquinol: Independent global veterinary pharmaceutical company with a companion animal therapeutics portfolio; comparable to Vaxcell as a specialty vet pharma player with both drug and care-product lines.
• Ceva Santé Animale: Global veterinary pharmaceutical group with strong companion animal franchise, including biologics; a close comparable to Vaxcell in specialty pet therapeutics and biologics development.
• Virbac: Global veterinary pharmaceutical company with a dedicated pet oncology and immunology portfolio; competes directly with Vaxcell's VCB-2401 in companion animal therapeutics and would be a comparable for any international pet oncology launch.
• Dechra Pharmaceuticals: Specialty veterinary pharmaceutical company focused on companion animal therapeutics across multiple therapeutic areas, including oncology; directly comparable to Vaxcell in business model and channel focus.

Others

• Nkarta Therapeutics: Clinical-stage biotech developing engineered NK cell therapies for cancer; not a direct veterinary competitor but a thematic comparable for Vaxcell's NK cell platform technology and human oncology aspirations.

Regional players

• Daewoong Pharmaceutical: Korean pharmaceutical company with an animal health division; regional peer that competes with Vaxcell in the Korean companion animal therapeutics market and shares similar Korean regulatory exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=t186jyWSEV0
• LinkedInlinkedin.com/company/vaxcell-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxcell Bio Therapeutics